Sun Pharmaceutical Industries Beheer
Beheer criteriumcontroles 4/4
Momenteel beschikken wij niet over voldoende informatie over de CEO.
Belangrijke informatie
Dilip Shanghvi
Algemeen directeur
₹60.5m
Totale compensatie
| Percentage CEO-salaris | 75.6% |
| Dienstverband CEO | 31.7yrs |
| Eigendom CEO | 9.6% |
| Management gemiddelde ambtstermijn | 2.8yrs |
| Gemiddelde ambtstermijn bestuur | 3.5yrs |
Recente managementupdates
Recent updates
Does Sun Pharmaceutical Industries (NSE:SUNPHARMA) Have A Healthy Balance Sheet?
Nov 18
Sun Pharmaceutical Industries Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Oct 31We Ran A Stock Scan For Earnings Growth And Sun Pharmaceutical Industries (NSE:SUNPHARMA) Passed With Ease
Oct 21Pinning Down Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) P/E Is Difficult Right Now
Aug 24Sun Pharmaceutical Industries Limited Just Beat EPS By 10%: Here's What Analysts Think Will Happen Next
Aug 06This Is The Reason Why We Think Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) CEO Might Be Underpaid
Jul 30Sun Pharmaceutical Industries (NSE:SUNPHARMA) Ticks All The Boxes When It Comes To Earnings Growth
Jun 30Sun Pharmaceutical Industries (NSE:SUNPHARMA) Has A Rock Solid Balance Sheet
Jun 12Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Annual Results Just Came Out: Here's What Analysts Are Forecasting For This Year
May 25Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) Price Is Out Of Tune With Earnings
May 22Sun Pharmaceutical Industries (NSE:SUNPHARMA) Has A Rock Solid Balance Sheet
Mar 13Sun Pharmaceutical Industries' (NSE:SUNPHARMA) Upcoming Dividend Will Be Larger Than Last Year's
Feb 03Here's Why We Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Might Deserve Your Attention Today
Jan 05Getting In Cheap On Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Is Unlikely
Dec 18Is Now The Time To Put Sun Pharmaceutical Industries (NSE:SUNPHARMA) On Your Watchlist?
Oct 04Should You Be Adding Sun Pharmaceutical Industries (NSE:SUNPHARMA) To Your Watchlist Today?
Jul 03We Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Can Manage Its Debt With Ease
Jun 15Is Sun Pharmaceutical Industries (NSE:SUNPHARMA) A Risky Investment?
Mar 14Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Increasing Its Dividend To ₹7.50
Feb 03These 4 Measures Indicate That Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Using Debt Reasonably Well
Dec 09Does This Valuation Of Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Imply Investors Are Overpaying?
Oct 13These 4 Measures Indicate That Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Using Debt Safely
Sep 04Sun Pharmaceutical Industries' (NSE:SUNPHARMA) Upcoming Dividend Will Be Larger Than Last Year's
Aug 05Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | ₹111b |
| Jun 30 2024 | n/a | n/a | ₹104b |
| Mar 31 2024 | ₹61m | ₹46m | ₹96b |
| Dec 31 2023 | n/a | n/a | ₹89b |
| Sep 30 2023 | n/a | n/a | ₹85b |
| Jun 30 2023 | n/a | n/a | ₹84b |
| Mar 31 2023 | ₹55m | ₹41m | ₹85b |
| Dec 31 2022 | n/a | n/a | ₹42b |
| Sep 30 2022 | n/a | n/a | ₹41b |
| Jun 30 2022 | n/a | n/a | ₹39b |
| Mar 31 2022 | ₹51m | ₹38m | ₹33b |
| Dec 31 2021 | n/a | n/a | ₹64b |
| Sep 30 2021 | n/a | n/a | ₹62b |
| Jun 30 2021 | n/a | n/a | ₹60b |
| Mar 31 2021 | ₹46m | ₹35m | ₹29b |
| Dec 31 2020 | n/a | n/a | ₹24b |
| Sep 30 2020 | n/a | n/a | ₹15b |
| Jun 30 2020 | n/a | n/a | ₹7b |
| Mar 31 2020 | ₹43m | ₹32m | ₹38b |
| Dec 31 2019 | n/a | n/a | ₹40b |
| Sep 30 2019 | n/a | n/a | ₹43b |
| Jun 30 2019 | n/a | n/a | ₹30b |
| Mar 31 2019 | ₹263k | ₹1 | ₹27b |
| Dec 31 2018 | n/a | n/a | ₹34b |
| Sep 30 2018 | n/a | n/a | ₹24b |
| Jun 30 2018 | n/a | n/a | ₹36b |
| Mar 31 2018 | ₹34m | ₹28m | ₹21b |
Compensatie versus markt: De totale vergoeding ($USD 718.09K ) Dilip } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de Indian markt ($USD 1.08M ).
Compensatie versus inkomsten: De vergoeding van Dilip is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Dilip Shanghvi (69 yo)
31.7yrs
Tenure
₹60,541,920
Compensatie
Mr. Dilip Shantilal Shanghvi serves as MD at Sun Petrochemicals Private Limited. He serves as Chairman of Board of Directors of Taro Pharmaceutical Industries Ltd at Taro Pharmaceuticals U.S.A., Inc. He se...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| MD & Chairman of the Board | no data | ₹60.54m | 9.6% ₹ 405.8b | |
| Executive VP | no data | ₹68.75m | 0.12% ₹ 5.1b | |
| Chief Financial Officer | 7.4yrs | ₹38.89m | geen gegevens | |
| Executive Vice-President of Global Operations | no data | geen gegevens | geen gegevens | |
| EVP & Chief Information Officer | less than a year | geen gegevens | geen gegevens | |
| VP, Head of Investor Relations & Strategic Projects | no data | geen gegevens | geen gegevens | |
| Company Secretary & Compliance Officer | 2.8yrs | geen gegevens | geen gegevens | |
| Director of Corporate Development | no data | ₹65.30m | geen gegevens | |
| Chief Human Resources Officer | less than a year | geen gegevens | geen gegevens | |
| Head of India Business | no data | geen gegevens | geen gegevens | |
| Chief Executive Officer of North America Business | 8.3yrs | geen gegevens | geen gegevens | |
| Head of Corporate Relations & CSR - India Regulatory Affairs | no data | geen gegevens | geen gegevens |
2.8yrs
Gemiddelde duur
60yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van SUNPHARMA wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.8 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| MD & Chairman of the Board | 31.7yrs | ₹60.54m | 9.6% ₹ 405.8b | |
| Executive VP | 1.4yrs | ₹68.75m | 0.12% ₹ 5.1b | |
| Non-Executive & Non-Independent Director | 30.8yrs | ₹2.20m | 1.8% ₹ 76.1b | |
| Non-Executive & Independent Director | 3.5yrs | ₹5.10m | geen gegevens | |
| Non-Executive Independent Director | 6.5yrs | ₹7.80m | geen gegevens | |
| Independent Director | 1.4yrs | ₹3.20m | geen gegevens | |
| Lead Independent Director | 3.5yrs | ₹8.50m | geen gegevens | |
| Independent Director | 2yrs | ₹4.80m | geen gegevens |
3.5yrs
Gemiddelde duur
67.5yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van SUNPHARMA wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.5 jaar).